Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Malignant Female Reproductive System Neoplasm

Known as: Malignant Neoplasm of Female Reproductive System, cancers female reproductive, Malignant Tumor of Female Reproductive System 
A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical… Expand
National Institutes of Health

Related topics

Related topics

9 relations
CARCINOMA OF VULVAFemale Reproductive SystemFemale genitaliaMalignant neoplasm of vulva
Expand

Broader (1)

Genital Neoplasms, Female

Narrower (1)

Malignant Vaginal Neoplasm

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium
Contemporary dietary guidelines recommend limiting consumption of unprocessed red meat and processed meat. For example, the… Expand
Is this relevant?
Review
2019
Review
2019
Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
BACKGROUND Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
Background Risk-reducing salpingo-oophorectomy (RRSO) is widely used by carriers of BRCA1 or BRCA2 (BRCA1/2) mutations to reduce… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
PURPOSE To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free… Expand
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Revised FIGO staging for carcinoma of the endometrium.
Carcinoma of the corpus uteri was staged clinically in the first instance, as had been done for cervical cancer. This appeared… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
2004 consensus statements on the management of ovarian cancer : final document of the 3rd International Gynecologic Cancer… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
BACKGROUND Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer in… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Risk-Reducing Salpingo-Oophorectomy in Women With a BRCA1 or BRCA2 Mutation
In the 6 years from mid-1995 to mid-2001, 177 women from the Genetics Service at Memorial Sloan-Kettering who were found to carry… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer, in part because of the lack of effective early… Expand
  • figure 1
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
CONTEXT Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the… Expand
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE